BIOHARVEST SCIENCES (BHST) Company Report

BioHarvest (BHST) reported Q3 2025 revenue of $9.1 million, marking a 39% year-over-year increase, with gross profit rising 50% to $5.6 million, or 61% of total revenue.
The company significantly narrowed its Adjusted EBITDA loss to $0.4 million in Q3 2025, compared to $1.7 million in the prior year quarter, and anticipates reaching adjusted EBITDA break-even in Q4 2025 or early 2026.
As of September 30, 2025, cash and cash equivalents totaled $11 million, further strengthened by a $19.9 million gross proceeds from an institutional equity raise in November.
Key growth drivers include a 722% increase in CDMO revenue to $0.7 million in Q3 2025, a new CDMO partnership with SaffronTech where BioHarvest retains 25% ownership of the resulting compound, and the launch of the VINIA BloodFlow Hydration product.

Nov 13, 2025, 9:30 PM

BioHarvest Sciences Reports Strong Revenue Growth and Improved Margins in Q3 2025, Bolsters Liquidity with Recent Offerings

BHST

Earnings

Revenue Acceleration/Inflection

Product Launch

BIOHARVEST SCIENCES INC. reported a 39% increase in revenues for Q3 2025, reaching $9,067 thousand, and a 42% increase for the nine months ended September 30, 2025, totaling $25,442 thousand, compared to the respective prior-year periods.
Gross margins improved to 61.4% in Q3 2025 and 59.9% for the nine-month period, up from 56.8% and 54.8% in the prior year, respectively.
The company continues to report a net loss of $(2,513) thousand for Q3 2025 and $(8,931) thousand for the nine months ended September 30, 2025, with an accumulated deficit of $105,349 thousand as of September 30, 2025.
To strengthen liquidity, BioHarvest Sciences completed an Equity Offering in September 2025, generating approximately $14,202 thousand in net proceeds, and a Public Offering on November 10, 2025, yielding approximately $18,437 thousand in net proceeds.
The company achieved $70 million USD in cumulative VINIA® sales by October 2025 and launched new products, including VINIA® 2X Formula Chew in June 2025 and VINIA® Blood Flow Hydration Electrolyte Powdered Beverage Mix in November 2025.

Nov 13, 2025, 9:01 PM

BioHarvest Sciences to Attend Craig-Hallum Conference

BHST

New Projects/Investments

Guidance Update

Revenue Acceleration/Inflection

BioHarvest Sciences Inc. (BHST) announced that CEO Ilan Sobel will attend the Craig-Hallum 16th Annual Alpha Select Conference on November 18, 2025, in New York, NY, to host one-on-one meetings with institutional investors.
The company reported strong momentum in its consumer and CDMO divisions, with its VINIA® capsule business performing robustly and new product lines expanding market reach, alongside breakthroughs in plant-based exosome production and a new saffron compound contract.
This update follows the successful close of an upsized $19.9 Million equity offering led by Craig-Hallum, with BioHarvest focused on achieving adjusted EBITDA breakeven in the near term.

Nov 12, 2025, 8:48 PM

BioHarvest Sciences Closes Upsized Public Offering

BHST

New Projects/Investments

Revenue Acceleration/Inflection

BioHarvest Sciences Inc. (BHST) announced the closing of its upsized public offering of 2,846,854 shares of common stock, which included 361,854 shares issued upon the exercise of the underwriters' option to purchase additional shares.
The shares were offered at a public offering price of $7.00 per share, generating gross proceeds of $19.9 million before deductions for underwriting discounts and other offering expenses.
The company expects to use the net proceeds for immediate funding of additional manufacturing expansion, research and development, marketing, debt reduction or refinancing, other capital expenditures, and general corporate purposes.

Nov 10, 2025, 10:28 PM

BIOHARVEST SCIENCES INC. Announces Strategic CDMO Agreement with Saffron Tech Ltd.

BHST

New Projects/Investments

BIOHARVEST SCIENCES INC. (BHST) entered into a strategic CDMO agreement with Saffron Tech Ltd. on September 29, 2025, to develop and commercialize saffron-derived botanical compounds using BioHarvest's patented Botanical Synthesis platform.
The partnership will combine BioHarvest's bioreactor-based manufacturing and cell-growth expertise with Saffron Tech's saffron cell-culture research, covering Stage 1 and Stage 2 of CDMO development.
Saffron Tech will own 75% of the developed saffron compositions, intellectual property, and commercial rights, while BioHarvest will hold the remaining 25%.
The development funding will be split 75% by Saffron Tech and 25% by BioHarvest. BioHarvest's standard fees for Phase I + II are $1,500,000 and for Phase III are $1,000,000.
BioHarvest plans to manufacture the compound at large scale and market it in its direct-to-consumer e-commerce business by developing a line of nutraceutical products.

Oct 31, 2025, 8:25 PM

BioHarvest Sciences Announces Strategic Partnership and Q3 2025 Preliminary Results

BHST

New Projects/Investments

Guidance Update

BioHarvest Sciences Inc. (BHST) has entered into a strategic CDMO agreement with Saffron Tech to develop and commercialize saffron-derived botanical compounds using BioHarvest's patented Botanical Synthesis platform.
Under the terms of the agreement, Saffron Tech will own 75% of the developed saffron compositions, ownership IP, and commercial associated rights, with BioHarvest holding the remaining 25%.
BioHarvest provided preliminary unaudited revenue guidance for the third quarter of 2025 of approximately $9.1 million, with an expected unaudited adjusted EBITDA range of ($0.7 million) to ($0.4 million).
The company also provided guidance for the fourth quarter of 2025, projecting revenue in the range of $9 million to $9.5 million and adjusted EBITDA between ($0.6 million) and $0.0 million.
As of September 30, 2025, cash and cash equivalents totaled approximately $11 million.

Oct 31, 2025, 4:58 PM

BioHarvest Sciences Fortifies Balance Sheet with $14.7 Million Capital Infusion and Debt Reduction

BHST

Debt Issuance

Convertible Preferred Issuance

New Projects/Investments

BioHarvest Sciences Inc. fortified its balance sheet by $14.7 million through a combination of $10.9 million in gross proceeds and $3.8 million in debt reduction.
The $10.9 million in gross proceeds was raised from $5.8 million in warrant exercises and $5.1 million from new convertible notes that were subsequently converted into common shares.
The $3.8 million debt reduction included $1.8 million from converting pre-existing convertible notes, $1.4 million from long-term debt repayment, and $0.6 million from short-term debt repayment.
As a result of these transactions, the company's total debt now stands at approximately $6.6 million, comprising $3.6 million in short-term debt and $3 million in long-term debt.
The $10.9 million in gross proceeds will be utilized for capital expenditures related to new capacity, refinancing remaining debt, and general working capital.